Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;33(4):320-328.
doi: 10.5152/tjg.2022.21124.

Factors Predictive of Proximal Disease Extension and Clinical Course of Patients Initially Diagnosed with Ulcerative Proctitis in an IBD Referral Center

Sandro da Costa Ferreira  1 , Lilian Rose Otoboni Aprile  1 , Rogério Serafim Parra  2 , Marley Ribeiro Feitosa  2 , Gleici de Castro da Silva Perdoná  3 , Omar Féres  2 , José Joaquim Ribeiro da Rocha  2 , Luiz Ernesto de Almeida Troncon  1
Affiliations

Factors Predictive of Proximal Disease Extension and Clinical Course of Patients Initially Diagnosed with Ulcerative Proctitis in an IBD Referral Center

Sandro da Costa Ferreira et al. Turk J Gastroenterol. 2022 Apr.

Abstract

Background: This study aims to determine whether risk factors at the time of diagnosis that are found to be predictive of proximal dis- ease extension in ulcerative proctitis (UP) occur in a cohort of Brazilian patients.

Methods: This is a retrospective analysis of data from 97 patients (67% female) with UP (Montreal classification: E1) with at least 12 months of follow-up who were admitted to the Ribeirão Preto Medical School IBD referral center between January 2001 and December 2018. Proximal disease extension, which was defined as E1 progressing to E3 (pancolitis), was evaluated endoscopically during follow-up.

Results: A total of 29 (29.9%) patients experienced proximal disease extension. The risk factors at diagnosis associated with proximal disease extension were younger age (<40 years; P = .012), higher Mayo endoscopic score (P < .0001), higher partial Mayo score (P = .0018), and use of oral corticosteroids (P = .0016). During the follow-up period, increased disease relapse rates (P < .0001), immuno- modulators (P = .00014) or the use of biological agents (P = .00037), and colectomy (P = .0002) were all significantly higher among UP patients with proximal disease extension.

Conclusion: Similar to what has been demonstrated in other studies, Brazilian UP patients with increased clinical and endoscopic sever- ity at the time of diagnosis are likely to evolve with both proximal extension and a more adverse clinical course. Therefore, these patients should be followed-up more carefully.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Analysis of the likelihood of disease extension using Kaplan–Meier curves stratified by predictive factors measured at the time of diagnosis. (A) Cumulative disease extension likelihood was significantly more frequent in patients with disease onset before 40 years of age. (B) Cumulative disease extension likelihood was significantly higher in patients with use of corticosteroids at the time of diagnosis.
Figure 2.
Figure 2.
Analysis of the likelihood of disease extension using Kaplan–Meier curves stratified by predictive factors measured at the time of diagnosis. (A) Cumulative disease extension likelihood was significantly associated with patients with higher Mayo endoscopic subscores than patients with lower Mayo endoscopic subscores (P < .001). (B) Cumulative disease extension likelihood was significantly associated with patients with higher Mayo partial scores than patients with lower Mayo partial scores (P = .0018).
Figure 3.
Figure 3.
Kaplan–Meier curves of the cumulative rates of relapse of the disease over the long-term during follow-up.
See this image and copyright information in PMC

References

    1. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756 1770. 10.1016/S0140-6736(16)32126-2) - DOI - PMC - PubMed
    1. Gajendran M, Loganathan P, Jimenez G, et al. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65(12):100851. 10.1016/j.disamonth.2019.02.004) - DOI - PubMed
    1. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749 753. 10.1136/gut.2005.082909) - DOI - PMC - PubMed
    1. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. BMJ. 1954;2(4884):375 378. 10.1136/bmj.2.4884.375) - DOI - PMC - PubMed
    1. Walmsley RS, Ayres RCS, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43(1):29 32. 10.1136/gut.43.1.29) - DOI - PMC - PubMed